4.4.0.0 As­pirin Use in Peo­ple <50 Years of Age

As­pirin is not rec­om­mend­ed for those at low risk of ASCVD (such as men and women aged <50 years with di­a­betes with no other major ASCVD risk fac­tors) as the low benefit is like­ly to be out-‍weighed by the risks of bleed­ing. Clin­i­cal judg­ment should be used for those at in­ter­me­di­ate risk (younger pa­tients with one or more risk fac­tors or older pa­tients with no risk fac­tors) until fur­ther re­search is avail­able. Pa­tients’ will­ing­ness to un­der­go long-‍term as­pirin ther­a­py should also be con­sid­ered (131). As­pirin use in pa­tients aged <21 years is gen­er­ally contrain­di­cated due to the as­so­ci­at­ed risk of Reye syn­drome.